Biodexa Pharmaceuticals PLC
BDRX
View Detailed Chart
6.600USD
+0.250+3.94%
Close 09/29, 16:00（ET）Quotes delayed by 15 min
40.89BMarket Cap
--P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+3.94%
5 Days
-0.15%
1 Month
+20.66%
6 Months
+436.59%
Year to Date
+62.96%
1 Year
-8.21%
View Detailed Chart
TradingKey Stock Score of Biodexa Pharmaceuticals PLC
Currency: USD Updated: 2025-09-26Key Insights
Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biodexa Pharmaceuticals PLC's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
180.000
Target Price
+2734.65%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biodexa Pharmaceuticals PLC Highlights
StrengthsRisks
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Overvalued
The company’s latest PE is -5474.14, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 46.40K shares, increasing 43.20% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Biodexa Pharmaceuticals PLC Info
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
Ticker SymbolBDRX
CompanyBiodexa Pharmaceuticals PLC
CEOMr. Stephen A. Stamp
Websitehttps://www.biodexapharma.com/
Related Instruments
+1.04%
+2.08%
+0.65%
+3.37%
+0.02%
+1.00%
+0.80%
+0.11%
-0.21%
-0.20%
+3.92%
+0.09%
-0.35%
+4.45%
-2.08%
+0.09%
+4.90%
0.00%
+8.54%
+0.73%Popular Symbols
